Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21554546 | 0.83 | CA2 (0.50) | MTNR1AMTNR1BLMNATSHRRXRA | |
| SCHEMBL1283948 | 0.83 | CA2 (0.50) | MTNR1AMTNR1BRIPK1RIPK3CYP4F2 | |
| SCHEMBL19085086 | 0.83 | MTNR1A (0.47) | MTNR1AMTNR1BRIPK1RIPK3CYP4F2 | |
| SCHEMBL7517689 | 0.83 | HPGD (0.50) | MTNR1AMTNR1BRIPK1RIPK3CYP4F2 | |
| SCHEMBL4409312 | 0.82 | CYP4F2 (0.44) | MTNR1AMTNR1BCYP4F2CYP4A11APP | |
| SCHEMBL2427540 | 0.81 | MAPT (0.56) | MTNR1AMTNR1BMAPTLMNATSHR | |
| SCHEMBL21880654 | 0.81 | MTNR1A (0.46) | MTNR1AMTNR1BRIPK1RIPK3CYP4F2 | |
| SCHEMBL5533824 | 0.81 | MTNR1A (0.46) | MTNR1AMTNR1BLMNASMN1; SMN2TSHR | |
| SCHEMBL3135380 | 0.81 | KMT2A (0.53) | MTNR1AMTNR1BRIPK1RIPK3MAPT | |
| SCHEMBL5866843 | 0.81 | LOXL2 (0.46) | MTNR1AMTNR1BRIPK1RIPK3CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107406-A1 | p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF | Design Therapeutics, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12459915-B2 | Biaryl derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | LG CHEM, LTD. (KR) | 2025-11-04 | — | — | US | disclosed |
| US-20250002487-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-01-02 | — | — | US | disclosed |
| EP-4436968-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118201924-A | Heterocyclic compounds and their use | 万特斯治疗美国公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20230322706-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
| CN-112010858-B | BTK inhibitor, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4206193-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | Lg Chem, Ltd. (KR) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023081441-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-116056706-A | Novel biaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2023-05-02 | — | — | CN | disclosed |
| WO-2022148459-A1 | CLASS OF NOVEL SMAD3 PROTEIN DEGRADERS AND APPLICATION THEREOF | 和径医药科技（上海）有限公司 | 2022-07-14 | — | — | WO | disclosed |
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| WO-2022050749-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | 주식회사 엘지화학 | 2022-03-10 | — | — | WO | disclosed |
| CN-112010858-A | BTK inhibitor, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2020-12-01 | — | — | CN | disclosed |
| EP-3030565-B1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-9688683-B2 | Substituted condensed pyrimidine compounds | Grünenthal GmbH (DE) | 2017-06-27 | — | — | US | disclosed |
| US-9617256-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-3030565-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-06-15 | — | — | EP | disclosed |
| US-20160152624-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-06-02 | — | — | US | disclosed |
| WO-2015018534-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | MTNR1A 2583/4885MTNR1B 2080/4885RIPK1 1871/4885 |
| US-20250002487-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CGAS, TDP1, CYP11B2 | MTNR1A 930/4885MTNR1B 1220/4885RIPK1 3876/4885 |
| US-20160152624-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | PDE4A, PDE4B, TYMP | MTNR1A 2887/4885MTNR1B 2469/4885RIPK1 4787/4885 |
| US-20230322706-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | DGAT2, DGAT1, MOGAT2 | MTNR1A 3143/4885MTNR1B 1896/4885RIPK1 3669/4885 |
| US-12459915-B2 | Biaryl derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | DGAT2, DGAT1, LCAT | MTNR1A 3271/4885MTNR1B 1963/4885RIPK1 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.